



## BioCryst to Present at Upcoming Investor Conferences

April 12, 2023

RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

- The 22<sup>nd</sup> Annual Needham Virtual Healthcare Conference on Wednesday, April 19<sup>th</sup> at 8:45 a.m. ET
- The BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10<sup>th</sup> at 6:00 p.m. ET
- The JMP Securities Life Sciences Conference in New York on Tuesday, May 16<sup>th</sup> at 2:30 p.m. ET
- The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 17<sup>th</sup> at 8:00 a.m. ET

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website at <http://www.biocryst.com>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO<sup>®</sup> (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB<sup>®</sup> (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company's website at [www.biocryst.com](http://www.biocryst.com).

BCRXW

### Contact:

John Bluth  
+1 919 859 7910  
[jbluth@biocryst.com](mailto:jbluth@biocryst.com)